^
Association details:
| Biomarker: | KIT N822Y |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
Published date:
01/18/2022
Excerpt:
Detection rate of ctDNA in imatinib-resistant patients was 57% (31/54). Among these 31 patients, 12 (39%) showed KIT gene mutation (8 with the known drug-resistant KIT mutations, 6 of these patients exhibited single-drug resistance while 2 showed multi-drug resistance due to KIT mutations mainly in Exon 13 V654A, Exons 17 Y823D, D820Y, N822Y, and N822K).
DOI:
10.1200/JCO.2022.40.4_suppl.662
